AstraZeneca taps Emergent Biosolutions for COVID-19 vaccine production

AstraZeneca (NYSE:AZN) will work with Emergent Biosolutions (NYSE:EBS) to help produce the 300M doses of ADZ1222 that AZN has pledged to the U.S.

The candidate was the first to advance into Phase 2 development. Preliminary data should be available no later than next month.

Earlier today, EBS announced an $87M deal with AZN for development services, technology transfer, analytical testing, drug substance process and performance qualification as well as reserving large-scale production capacity through this year.

Last week, EBS inked a $628M contract with the U.S. government to accelerate the delivery of COVID-19 vaccines.

https://seekingalpha.com/news/3582463-astrazeneca-taps-emergent-biosolutions-for-covidminus-19-vaccine-production